Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Lipella's new drug shows promise in treating oral lichen planus, leading to a significant stock surge.
Lipella Pharmaceuticals has reported successful Phase 2a trial results for LP-310, a drug treating oral lichen planus, showing significant improvements in pain, inflammation, and ulceration with no serious side effects.
The company's stock surged over 65% in pre-market trading following the announcement.
Further trials with higher doses are ongoing.
6 Articles
El nuevo fármaco de Lipella es prometedor en el tratamiento del liquen plano oral, lo que conduce a un aumento significativo de las existencias.